Serological Prevalence of Hepatitis B and C Viral Infections in North Central Nigeria
Abstract:
Viral
hepatitis is an inflammatory disease of the liver that triggers a series of complex
immune responses that could eventually result in damages to the liver tissue if
persistent. It has been estimated that Hepatitis B Virus (HBV) and Hepatitis C Virus
(HCV) infections mortality combined far exceeded the number of mortalities occasioned
by HIV/AIDS, Tuberculosis, and Malaria combined globally. The global HBV and HCV
pandemic has its highest prevalence in the WHO Western Pacific and the WHO African
regions. The WHO Eastern Mediterranean and the WHO European Regions carries the
highest burdens of the HCV infection. The prevalence of HBV in Nigeria is very high
as reported in several studies, and the prevalence of HCV is reported to be rising
steadily. The low level of public awareness about the danger of HBV and HCV infections
has contributed to the steady rise in the incidence of these infections among the
Nigerian population. This study shows a 16% HBV prevalence, with a 2% HCV prevalence
among the study population. The male population in this study have a higher prevalence
of HBV infection (20%), with the female population having a 13% HBV prevalence.
Only the female population has a prevalence of 4% for HCV infection in this study.
The high prevalence of HBV and HCV infections in this study clearly requires all
stakeholders to intensify advocacy and public health education on ways of preventing
and managing HBV and HCV infections among the Nigerian population.
References:
[1].
Buffington,
J., and Jones, S.T. (2007). Integrating Viral Hepatitis Prevention into Public Health
Programs Serving People at High Risk for Infection: Good Public Health. Public Health Rep. 2007; 122 (Suppl 2): Pp.
1-5.
[2].
CDC
(2019). What is viral hepatitis? Retrieved from: www.cdc.gov/hepatitis/abc/index.htm.
[3].
CDC
(2020). Hepatitis C Question and Answers for the Public. Retrieved from:
www.cdc.gov/hepatitis/hcv/cfaq.htm.
[4].
Charles,
PD. (2019). Hepatitis (Viral Hepatitis A, B, C, D, E, G). Retrieved from:
www.medicinenet.com/viral_hepatitis/article.htm#viral_hepatitis_facts.
[5].
Chisari,
F.V. (1997). Cytotoxic T Cells and Viral Hepatitis. J. Clin. Invest. Volume 99, Number 7, April 1997, Pp. 1472-1477.
[6].
Christian,
N. (2017). What’s to know about viral hepatitis? Medical News Today. Retrieved from:
www.medicalnewstoday.com/article/14586
[7].
Ejiofor,
O.S.; Emechebe, G.O.; Igwe, W.C.; Ifeadike, C.O.; and Ubajaka, C.F. (2010). Hepatitis
C virus infection in Nigerians. Niger Med
J. 2010, 51: 173-6.
[8].
El-serag,
H.B. (2012). Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma. Gastroenterology, Volume 143, Issue 1, July
2012, Pp. 269.
[9].
European
Monitoring Centre for Drugs and Drug Addiction [EMCDDA] (2019). Increasing access
to hepatitis C care through drug services. Retrieved from:
emcdda.europa.eu/activities/promoting-hcv-hepatitis-c-virus-testing-and-linkage-care-drugs-services_en.
[10].
Guidotti,
LG; and Chisari, FV. (2006). Immunology and Pathogenesis of viral hepatitis. Annu Rev Pathol. 2006; 1: 23-61.
[11].
Heffernan,
A.; Cooke, G.S.; Nayagam, S.; Thursz, M.; and Hallet, T.B. (2019). Scaling up prevention
and treatment towards the elimination of hepatitis C: a global mathematical model.
The Lancet. Volume 393, Issue 10178, Pp. 1319-1329.
[12].
Kennard,
J. (2020). How Hepatitis is transmitted. Retrieved from: very well health.com/how-hepatitis-is-transmitted-3964786.
[13].
Koziel,
M.J., and Peters, M.G. (2007). Viral Hepatitis in HIV Infection. N. Engl. J. Med.
2007; 356: Pp. 1445-1454.
[14].
Krajden,
M; McNabb, G; and Petric, M. (2005). The Laboratory Diagnosis of Hepatitis B Virus.
Can. J. Infect. Dis.Med. Microbiol. 2005 Mar-Apr; 16(2): Pp. 65-72.
[15].
Mast,
E.E.; Hwang, L. YL; Seto, D.S.; et al. (2005). Risk Factors for Perinatal Transmission
of Hepatitis C Virus (HCV) and the Natural History of HCV Infection Acquired in
Infancy. J. Infect. Dis. 2005; 192: Pp. 1880-1889.
[16].
Ministry
of Health Malaysia [MHM] (2019). National Strategic Plan for Hepatitis B and C.
Retrieved from:
www.moh.gov.my/moh/resources/penerbitan/pelan%20strategik%20/NSP_Hep_BC_2019_2023.pdf.
[17].
Musa,
BM; Bussel, S; Borodo, MM; Samaila, AA; and Femi, OL. (2015). Prevalence of HBV
infection in Nigeria, 2000-2013: A systematic review and meta-analysis. Nigerian
Journal of Clinical Practice, 2015, Vol 18(2): 163-172.
[18].
Odjimogho,
S.; Agofure, O.; Oghenenioborue, R.A.; Okandeji, B.; and Ibrahim, Z.L. (2018). Prevalence
of hepatitis B and C among HIV/AIDS patients attending Bingham University Teaching
Hospital, Jos, Plateau State, Nigeria: A retrospective study. Journal of Public
Health and Epidemiology. Vol 10(6): 198-204.
[19].
Pedrana,
A.; Howell, J.; Schroder, S.; Scott, N. et al. (2018). Eliminating Viral Hepatitis:
The Investment Case. Doha, Qatar: World Innovation Summit for Health, 2018.
[20].
Peeling,
R.W.; Boeras, D.I.; Marinucci, F.; and Easterbrook, P. (2017). The future of viral
hepatitis testing: Innovation in testing technologies and approaches. BMC Infectious
Diseases. 17 Article Number: 699 (2017).
[21].
Samji,
N.S. (2017). Viral Hepatitis Medication. Retrieved from:
emedecine.medscape.com/article/775507-medication.
[22].
Samji,
N.S. (2017). Viral Hepatitis Treatment and Management. Retrieved from:
emedecine.medscape.com/article/775507-treatment.
[23].
Sim,
M.; Cheng, W.; Dore, G.; and Beers, K. (2019). Signs and Symptoms of Chronic Viral
Hepatitis. In HIV, Viral Hepatitis and STIs: a guide to primary care. Chapter 7,
Pp. 71-79.
[24].
Smith,
M.F. (1968). Viral Hepatitis. Annexed Thesis Digitization Project 2019 Block 22,
1968. Retrieved from:
www.era.ed.ac.uk/bitstream/handle/1842/34017/SmithMF_1968redux.pdf?sequence=1.
[25].
Ukaeje,
C.J.; Ogbu, U.; Inyama, P.U.; Anyawu, G.I.; and Njoku, I.O. (2005). Prevalence of
hepatitis B surface antigen among blood donors and human immunodeficiency virus
infected patients in Jos, Nigeria. Mom do Inst Oswaldo Cruz. 2005, 100: 13-6.
[26].
Van
Herck, K.; Vorsters, A.; and Van Damme, P. (2008). Prevention of Viral Hepatitis
(Band C) Reassessed. Best Pract Res Clin Gastroenterol. 2008; 22(6): Pp. 1009-1029.
[27].
WHO
(2020). Hepatitis. Retrieved from: www.afro.who.int/health-topics/hepatitis.
[28].
WHO
(2020). Manual for the Development and Assessment of National Viral Hepatitis Plans:
A Provisional Document. Available at:
www.who.int/hepatitis/publications/manual-hep-plan/en/.
[29].
WHO
(2018). What is hepatitis? Retrieved from: www.who.int/features/qa/76/en/.
[30].
WHO
(2017). New hepatitis data highlight needs for urgent global response. Retrieved
from: https://www.who.int/news-room/detail/21-04-2017-new-hepatitis-data-highlight-need-for-urgent-global-response.
[31].
WHO
(2012). Prevention and Control of Viral Hepatitis Infection: Framework for Global
Action. Retrieved from:
apps.who.int/iris/bitstream/handle/10665/130012/WHO_HSE_PED_HIP_GHP_2012.1_eng.pdf?sequence=1.
[32].
World
Hepatitis Alliance [WHA] (2018). Prevention, Diagnosis, Treatment of Hepatitis B
and C. Retrieved from:
www.worldhepatitisalliance.org/viral-hepatitis/prevention-diagnosis-treatment-hepatitis-b-and-c.
[33].
World
Hepatitis Alliance [WHA] (2019). What is viral hepatitis? Retrieved from: world
hepatitis alliance.org/what-viral-hepatitis-0.